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Genome-wide association studies are providing new insights into the genetic basis of metabolic and cardi-
ovascular traits. In the past 3 years, common variants in 50 loci have been strongly associated with meta-
bolic and cardiovascular traits. Several of these loci have implicated genes without a previously known
connection with metabolism. Further studies will be required to characterize the full impact of these loci
on metabolism. Many of the identified loci include multiple independent variants that influence the same
metabolic or cardiovascular trait and a few loci harbor independent variants that each influence distinct
traits. The total proportion of trait heritability explained by variants identified so far is still modest (typically
<10%). Future studies will build on these successes by identifying additional common and rare variants and
by determining the functional impact of the underlying alleles and genes.
INTRODUCTION
Metabolic and cardiovascular diseases (CVD) are common,
complex traits with a substantial public health burden.
Although disease prevalence varies with age, gender and
population, the World Health Organization estimates that in
2005, 17.5 million deaths (30% of the global total) were
due to CVD (1). In many individuals, CVD coexists with a
set of metabolic risk factors including diabetes, central
obesity, unhealthy lipid profiles, high blood pressure, a pro-
thrombotic state, and a proinflammatory state, each of which
is likely regulated by genetic and environmental risk factors
(2). There is a strong genetic component to these traits; one
recent large-scale study found that on an average, genetic
effects explain 25% of the variance for 20 measures of cardi-
ovascular function, 51% for five anthropometric measures, and
40% for 38 blood tests including cholesterol and other meta-
bolic measures (3).
Until recently, the catalog of common genetic variants influ-
encing metabolism and CVD was limited and obtained pain-
fully slowly. Candidate gene studies and linkage analyses
identified only modest numbers of susceptibility loci that
were consistently replicated in additional large studies. In con-
trast, genome-wide association (GWA) studies have dramati-
cally increased the number of common variants with
confirmed association with metabolic and cardiovascular
traits. In this article, we review the recent progress identifying
loci through GWA studies and outline the challenges for the
future. Given space limitations, our aim is to provide a
flavor of the discoveries made to date, and to synthesize
important trends and future directions. Thus, we focus on
GWA studies of .200 000 single nucleotide polymorphisms
(SNPs) that reported at least one SNP exceeding an arbitrary
statistical significance threshold of P ¼ 5  1028. We have
tried to include independent GWA studies that identified the
same locus within 3 months of the first report. Of the
traits relevant to metabolism and cardiovascular risk, we
focus primarily on type 2 diabetes, coronary artery disease
(CAD) and myocardial infarction (MI), cholesterol and lipid
levels, and obesity-related traits.
TYPE 2 DIABETES
In the past decade, candidate gene studies and linkage analyses
provided definitive evidence for common susceptibility var-
iants in at least five loci. Specifically, candidate gene studies
based on prior understanding of biological function or of
monogenic forms of diabetes identified common variants in
the genes encoding peroxisome proliferator-activated
receptor-g (PPARG) (4,5), potassium inwardly-rectifying
channel, subfamily J, member 11 (KCNJ11) (6), Wolfram syn-
drome 1 (WFS1) (7), and transcription factor 2, hepatic
(TCF2) (8). Linkage analysis and fine mapping identified
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common type 2 diabetes (T2D)-associated variants within
transcription factor 7-like 2 (TCF7L2) (9), a locus not pre-
viously suspected to influence T2D or related traits and
which remains the most strongly associated T2D susceptibility
locus to date (Table 1).
In 2007, the first GWA studies describing T2D suscepti-
bility loci were reported. Five GWA studies were conducted
in populations of European ancestry, with the most significant
SNPs followed up by genotyping of additional samples (10–
15). These studies replicated evidence for TCF7L2, PPARG
and KCNJ11, and identified at least six additional loci
(Table 1). Strongly significant variants were identified at
solute carrier family 30 (zinc transporter), member 8
(SLC30A8), insulin-like growth factor 2 mRNA binding
protein 2 (IGF2BP2), fat mass and obesity-associated (FTO),
near hematopoietically expressed homeobox and insulin
degrading enzyme (HHEX-IDE), CDK5 regulatory subunit-
associated protein 1-like 1 (CDKAL1), and distal to the
genes cyclin-dependent kinase inhibitors 2A and 2B
(CDKN2A-CDKN2B, which encode proteins also known as
p16INK4a and p15INK4b). Among the reported SNPs, the
only likely functional variant identified is a non-synonymous
Arg325Trp substitution in SLC30A8. Although most of these
loci implicate pancreatic beta-cell biological processes, the
T2D-associated common variants in FTO are also strongly
associated with body mass index (BMI) (16,17).
More recently, a large meta-analysis of 2.2 million geno-
typed or imputed SNPs in 10 128 individuals with further gen-
otyping in up to 79 792 individuals identified six additional
loci meeting a statistical significance threshold of P ¼ 5 
1028 (18). These six signals are located in or near the genes
JAZF1, CDC123-CAMK1D, TSPAN8-LGR5, THADA,
ADAMTS9 and NOTCH2 (Table 1). The first three of these
loci listed are associated with measures of insulin release,
again implicating abnormal pancreatic beta-cell function in
the pathogenesis of T2D (19). The total number of T2D sus-
ceptibility loci is now at least 17, and larger scale
meta-analyses currently underway have the potential to ident-
ify additional susceptibility variants.
CAD AND MI
Compared with T2D, fewer genetic variants meet our threshold
of P ¼ 5  1028 in published GWA studies of CAD and MI.
An early study of 65 671 gene-based SNPs in individuals of
Japanese ancestry identified association with MI at SNPs in
lymphotoxin-A (LTA), including one SNP whose alleles were
also associated with LTA transcription level (20), although
later studies provided inconsistent replication (21).
Three recent independent GWA studies of CAD or MI
identified strong evidence of association with SNPs near the
CDKN2A and CDKN2B genes (13,22,23) (Table 1). These
studies reported SNPs in strong linkage disequilibrium (LD)
with each other in populations of European ancestry (Fig. 1),
and secondary signals in the adjacent LD block were identified
as well (23). The variants most strongly associated with CAD
are not in strong LD (r2 , .01) with the variants most strongly
associated with T2D described earlier, although secondary
signals for both traits are in LD with each other (e.g. r2
between secondary coronary heart disease SNP rs518394
and secondary T2D SNP rs564398 ¼ 0.75 in HapMap CEU).
As shown in Figure 1, this genomic region also contains
SNPs associated with frailty (24) and melanoma (25). In
addition to the CDKN2A and CDKN2B genes, which play a
role in the cell cycle, this region contains the non-coding anti-
sense RNA named ANRIL, which has been shown to be
expressed in tissues involved in atherosclerosis (26,27). A
replication study confirmed that the CAD and T2D associ-
ations were independent of each other and that these SNPs
were not associated with differences in plasma levels of
cholesterol, fibrinogen, albumin, uric acid, bilirubin, or homo-
cysteine (27).
One GWA study identified additional SNPs associated with
CAD using replication samples from an MI study (28). One
SNP is in the gene for methylenetetrahydrofolate dehydrogen-
ase (NADPþ-dependent) 1-like protein (MTHFD1L). The
encoded protein is involved in the synthesis of purines and
regeneration of methionine, and may influence homocysteine
levels. Another locus with strong evidence of association
maps near the PSRC1 gene; as described in the next section,
the same SNP is also associated with low density lipoprotein
cholesterol (LDL-C). Several other additional loci have been
reported that do not quite reach the threshold of P ¼ 5 
1028. Further functional experiments will be required to
discern the molecular mechanisms mediating the impact on
CAD and MI of this collection of signals.
CHOLESTEROL LIPOPROTEINS AND LIPIDS
Among the cardiovascular and metabolic traits, analyses of
lipoprotein and lipid levels have been among the most success-
ful in terms of the number of loci identified or confirmed by
GWA studies (Table 1). An initial GWA study reported an
association of the glucokinase regulator (GCKR) with serum
triglycerides (12). Two subsequent GWA studies analyzed
high density lipoprotein cholesterol (HDL-C), LDL-C, and tri-
glycerides concentrations in 8816 individuals and performed
follow-up analysis in independent sample sets (29,30).
Together, these studies showed strong support for association
with variants in or near GCKR and 11 additional previously
reported loci, as well as seven new loci. The previously ident-
ified loci included three apolipoprotein genes or gene clusters
(APOB, APOE-APOC1-APOC4-APOC2, APOA1-APOC3-
APOA4-APOA5); hepatic, endothelial and lipoprotein lipases
(LIPC, LIPG, LPL); cholesterol ester transfer protein
(CETP); LDL receptor (LDLR); hydroxy-3-methylglutaryl-
coenzyme A reductase (HMGCR); proprotein convertase subtili-
sin/kexin type 9 (PCSK9); and ATP-binding cassette, subfamily
A, member 1 (ABCA1). For several of these loci, the common
variant identified by GWA is in weak LD with previously ident-
ified common variants and likely represents a new signal; e.g. at
the LIPC locus, a set of common variants 50 kb upstream of
the gene are strongly associated with HDL-C and appear to be
independent of previously identified variants that overlap the
transcribed sequence of the gene (29).
The two studies also reported seven novel loci associated
with lipoprotein or lipid levels (29,30). SNPs near the mevalo-
nate kinase (MVK) – methylmalonic aciduria cblB type
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(MMAB) locus and in the N-acetylgalactosaminyltransferase
GALNT2 were found to be associated with HDL-C. SNPs
near the SORT1-PSRC1-CELSR2 locus were found to be associ-
ated with LDL-C, and two additional studies independently
identified this locus (31,32). An SNP at this locus, rs646776,
was strongly associated with transcript concentrations of the
three neighboring genes and explained 58–86% of the inter-
individual variability in their transcript levels (30). Of 11
Table 1. Loci associated with metabolic or cardiovascular traits and identified or confirmed by GWA with significance P , 5  1028
Trait Nearby gene(s) Representative SNP P-value OR 95% CI Effect References
T2D TCF7L2 rs7903146 4.6  10249 1.37 1.32–1.43 – (11–14)
T2D CDKN2A-CDKN2B rs2383208 2.7  10215 1.20 1.15–1.25 – (11–14)
T2D FTO rs8050136 1.5  10212 1.17 1.12–1.22 – (11–14)
T2D THADA rs7578597 1.1  1029 1.15 1.10–1.20 – (18)
T2D IGF2BP2 rs4402960 8.9  10215 1.14 1.10–1.18 – (11–14)
T2D KCNJ11 rs5219 5.4  10211 1.14 1.10–1.19 – (11–14)
T2D PPARG rs1801282 2.3  1026 a 1.14 1.08–1.20 – (11–14)
T2D CDKAL1 rs4712523 1.6  10212 1.13 1.09–1.17 – (11–14)
T2D HHEX-IDE rs1111875 6.9  10210 1.13 1.09–1.17 – (11–14)
T2D NOTCH2 rs10923931 4.1  1028 1.13 1.08–1.17 – (18)
T2D SLC30A8 rs13266634 2.4  1027 a 1.12 1.07–1.17 – (11–14)
T2D CDC123-CAMK1D rs12779790 1.2  10210 1.11 1.07–1.14 – (18)
T2D JAZF1 rs864745 5.0  10214 1.10 1.07–1.13 – (18)
T2D TSPAN8-LGR5 rs7961581 1.1  1029 1.09 1.06–1.12 – (18)
T2D ADAMTS9 rs4607103 1.2  1028 1.09 1.06–1.12 – (18)
CAD CDKN2A-CDKN2B rs1333049 2.9  10219 1.36 1.27–1.46 – (13,22,23,28)
CAD MTHFD1L rs6922269 2.9  1028 1.23 1.15–1.33 – (13,28)
CAD CELSR2-PSRC1-SORT1 rs599839 4.1  1029 1.29 1.18–1.40 – (13,28)
HDL-C CETP rs3764261 2.3  10257 – – 3.47 mg/dl (29,30,32,33)
HDL-C LPL rs10503669 4.1  10219 – – 2.09 mg/dl (29,30,32,33)
HDL-C LIPC rs4775041 3.2  10220 – – 1.38 mg/dl (29,30)
HDL-C LIPG rs2156552 6.4  10212 – – 1.20 mg/dl (29,30)
HDL-C GALNT2 rs2144300 2.6  10214 – – 1.11 mg/dl (29,30)
HDL-C ABCA1 rs4149268 1.2  10210 – – 0.82 mg/dl (29,30,33)
HDL-C MMAB-MVK rs2338104 3.4  1028 – – 0.48 mg/dl (29)
LDL-C LDLR rs6511720 4.2  10226 – – 9.17 mg/dl (29–31)
LDL-C APOE-C1-C4 rs4420638 3.0  10243 – – 6.61 mg/dl (29–32)
LDL-C CELSR2-PSRC1-SORT1 rs599839 6.1  10233 – – 5.48 mg/dl (29–32)
LDL-C APOB rs562338 5.6  10222 – – 4.89 mg/dl (29–32)
LDL-C NCAN-CILP2 rs16996148 2.7  1029 – – 3.32 mg/dl (29,30)
LDL-C PCSK9 rs11206510 3.5  10211 – – 3.04 mg/dl (29,30)
LDL-C HMGCR rs12654264 1  10220 – – 3.30 mg/dl (30)
Triglycerides APOA5-A4-C3-A1 rs12286037 1.0  10226 – – 25.82 mg/dl (29,30,32,33)
Triglycerides LPL rs10503669 3.9  10222 – – 11.57 mg/dl (29,30,32,33)
Triglycerides GCKR rs780094 6.1  10232 – – 8.59 mg/dl (29,30,32)
Triglycerides MLXIPL rs17145738 2.0  10212 – – 8.21 mg/dl (29,30,33)
Triglycerides ANGPTL3 rs1748195 1.7  10210 – – 7.12 mg/dl (29,30)
Triglycerides TRIB1 rs17321515 7.0  10213 – – 6.42 mg/dl (29,30)
Triglycerides NCAN-CILP2 rs16996148 2.5  1029 – – 6.10 mg/dl (29,30)
Triglycerides LIPC rs4775041 1.6  1028 – – 3.62 mg/dl (29)
Triglycerides GALNT2 rs4846914 7  10215 – – 6.40 mg/dl (30)
BMI FTO rs9939609 3  10235 – – 0.4 kg/m2 (16,17)
BMI/waist circumference MC4R rs1778231 2.8  10215 – – .05 logBMI Z score (40,41)
Fat mass CTNNBL1 rs6013029 5.0  1028 – – 5.96 kg (42)
QT interval NOS1AP rs10494366 ,1  10210 b – – 2.45 msb (44)
Fasting glucose G6PC2 rs563694 6.4  10233 – – 0.01–0.16 mM (46,47)
Serum uric acid SLC2A9 rs6855911 1.8  10216 – – 0.3 mg/dl (32,48–50)
CRP APOE rs769449 8.9  10221 – – –0.261c (51,52)
CRP CRP rs3091244 6.2  10228 – – 0.203c (51,52)
CRP LEPR rs1892534 6.5  10221 – – 20.170c (52)
CRP HNF1A rs7310409 6.8  10217 – – 20.154c (51,52)
CRP GCKR rs780094 6.7  10215 – – 0.140c (52)
CRP 12q23 rs10778213 1.2  10210 – – –0.115c (52)
CRP IL6R rs8192284 1.9  1028 – – 20.101c (52)
Table includes a single SNP reported at a given locus, with a corresponding significance level and odds ratio (OR) or measure of effect from one of the
listed references. Within each trait, loci are sorted by OR or effect size. GWA studies are included as references if they reported a result within a few
months of the first report. T2D, type 2 diabetes; CAD, coronary artery disease; HDL-C, high density lipoprotein cholesterol; LDL-C, low density
lipoprotein cholesterol; BMI, body mass index; CRP, C-reactive protein.
aSignificance exceeds 5  1028 threshold with additional samples.
bSignificance and average per allele difference from subset of samples in Table 1 of reference (44).
cRegression coefficient.
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SNPs at seven loci associated with LDL-C, Willer et al. noted
that all of the alleles associated with increased LDL-C were
also associated with CAD in a Wellcome Trust Case Control
Consortium (WTCCC) sample (13). SNPs primarily associated
with triglycerides were identified near the G-protein-coupled-
receptor-induced protein tribbles 1 (TRIB1), near angiopoietin-
like 3 (ANGPTL3), and in MLX interacting protein-like
(MLXIPL). Kooner et al. (33) independently reported
MLXIPL association with triglycerides, including a non-
synonymous SNP (rs3812316, Gln241His). SNPs at a locus
encompassing more than a dozen genes near NCAN were
strongly associated with both triglycerides and LDL-C
(Fig. 2); the large number of genes, none of which are over-
whelming candidates for a role in lipoprotein or lipid biology,
highlights the challenge ahead to determine the underlying
functional gene. Taken together, the combined effects of
these common variants account for only 5–8% of the variation
in the three lipid traits, leaving most of the heritability of these
traits to be explained.
OBESITY, BMI, WAIST CIRCUMFERENCE
AND FAT MASS
Over the last two decades, candidate gene and linkage studies
have reported many loci for obesity and related traits, but few
have been reproducibly confirmed. A review of the obesity lit-
erature through October 2005 summarized associations with
127 candidate genes and 253 quantitative trait loci for
obesity-related phenotypes from linkage studies (34).
Recently, common non-synonymous variants in proprotein
convertase subtilisin/kexin type 1 (PCSK1) were found to be
associated with obesity (P , 8  1028) in adults and children
(35). An early GWA report from the Framingham Heart Study
Figure 1. Evidence for association with several traits on chromosome 9p21. Evidence for association with type 2 diabetes (T2D) is shown for single nucleotide
polymorphisms (SNPs) evaluated in 10 128 GWA samples (18); P-values are substantially more significant when follow-up samples are included (see Table 1).
Arrows indicate the locations of SNPs reported to be associated with frailty, coronary heart disease (CHD), myocardial infarction (MI), and coronary artery
disease (CAD). Black bars indicate the locations of recombination hotspots, and the locations of genes and transcripts are indicated at the bottom.
Figure 2. Evidence for association with low density lipoprotein cholesterol (LDL-C) at a locus spanning many genes. Evidence for association is shown
for evaluated single nucleotide polymorphisms (SNPs) in 8816 GWA samples (29). SNPs are colored according to their degree of linkage disequilibrium
with rs2228603, the SNP most strongly associated with LDL-C in this region. The bottom panel depicts the locations of genes. Figure adapted from Willer
et al. (29).
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offspring study described a locus near the insulin-induced
gene 2 (INSIG2) gene associated with BMI (36), and a
follow-up study of 17 000 individuals in nine cohorts
from eight populations across multiple ethnicities confirmed
the association in both unrelated and family-based samples,
but with a modest effect (37).
In 2007, two independent GWA studies identified obesity-
associated variants within the first intron of the FTO gene
(16,17). The association between FTO variants and BMI
was independently identified in a third study (38) and has
since been replicated in many cohorts. FTO encodes a
2-oxoglutarate-dependent nucleic acid demethylase, and the
functional link between this methylase (or another nearby
gene) and obesity is not yet known (39), emphasizing the benefits
of unbiased genome-wide studies to identify susceptibility genes.
Two recent large GWA studies for obesity-related traits
identified associated SNPs near the melanocortin-4 receptor
(MC4R) gene. A study of BMI in 16 876 samples with
follow-up in .60 000 adults and almost 6000 children ident-
ified variants .100 kb downstream of MC4R (40), and a
study of waist circumference and insulin resistance in 2684
individuals described similar associations (41). MC4R
contains uncommon amino acid substitutions Val103Ile and
Ile251Leu known previously to influence obesity, but the
associations with common variants downstream of MC4R
cannot be explained by these substitutions (40). Together
FTO and MC4R variants explain only a small portion of inter-
individual variation in BMI, 1.2 kg/m2 in adults (40).
A third recent GWA study for BMI and fat mass in a sample
of 1000 unrelated United States Caucasians with follow-up in
.3800 individuals in a French case–control sample identified
variants in catenin, beta-like 1 (CTNNBL1) (42). The initial
evidence of association (P ¼ 5.0  1028 for fat mass)
became weaker after correction for stratification using
genomic control (43). Replication in additional cohorts will
be important to determine the impact of this locus.
OTHER QUANTITATIVE TRAITS
GWA studies have been reported for several other quantitative
traits relevant to metabolic and cardiovascular traits (Table 1).
One of the first successes was a multi-stage GWA study of the
QT interval, a risk factor for sudden cardiac death that ident-
ified association with variants near the NOS1AP gene (44).
More recently, a very large number of traits associated with
cardiovascular and metabolic traits have been dissected
using GWA. For fasting glucose level, common sequence var-
iants in the glucokinase (GCK) promoter were reported to be
strongly associated (P  1029) based on candidate gene ana-
lyses (45), and two GWA studies identified variants in islet-
specific glucose-6-phosphatase, catalytic, 2 (G6PC2) (46,47).
The first GWAs for serum uric acid levels identified strongly
significant variants at solute carrier family 2 (facilitated
glucose transporter), member 9 (SLC2A9) (32,48). An
additional independent GWA study reported a significantly
stronger association between SLC2A9 variants and urate con-
centration in women compared with men (49), and another
independent GWA demonstrated that SLC2A9 can transport
uric acid in a Xenopus laevis model (50).
Plasma concentrations of C-reactive protein (CRP) reflect sys-
temic inflammation, which co-occurs with CVD; two GWA
studies of plasma CRP level identified seven significant (P ,
5  1028) loci (51,52). The most strongly associated loci
include the CRP gene itself and the APOE locus, both of which
were previously known from candidate gene studies, as well as
the leptin receptor (LEPR). In addition, association with CRP
is observed for variants associated with other traits or disease,
including HNF1 homeobox A (HNF1A), variants of which are
known to cause maturity-onset diabetes of the young, and
GCKR, associated with triglycerides as described earlier. CRP
levels are also associated with the interleukin 6 receptor (IL6R)
and a gene desert region on chromosome 12q23.2.
Genes for several additional cardiovascular and metabolic
traits from GWA studies have not yet been reported. Notably
lacking from the GWA harvest to date are loci for hypertension
and systolic and diastolic blood pressure, and very large
meta-analyses may be needed to detect reproducibly associated
SNPs. The WTCCC reported no results achieving a threshold of
5  1027 for hypertension (13), suggesting that there may be
fewer common alleles with large effect on this trait.
CHALLENGES FOR THE FUTURE
Many challenges remain to identify the genetic variants that
influence cardiovascular and metabolic traits. Larger sample
sizes will be needed to continue to implicate additional loci,
and as cohorts are combined, heterogeneity across studies
may become a problem. Careful consideration of the potential
sources of heterogeneity will be necessary. Many of the GWA
studies reported to date are from samples of European ances-
try, and it will be important to assess the identified variants in
other populations, notably those of African and Asian ances-
try, and further loci may be identified by carrying out de
novo GWA studies in these populations. Also, the current
GWA studies do not thoroughly evaluate structural variants
and rare alleles, which are important targets of resequencing;
identifying these and also the alleles that form the basis for
each initial association are likely to increase the heritability
that can be explained.
Further analyses also may lead to additional biological
insights. Studies of gene–gene interactions may indicate
how combinations of genetic variants impact disease risk,
and studies of gene-by-environment interactions, especially
interactions with dietary and physical activity factors, may
further elucidate the mechanisms of inter-individual trait
variability. Many challenges await to identify the functional
alleles and genes at the implicated loci, as several loci
contain many genes and tens to hundreds of genetic variants
associated with a disease or trait. The predictive value of
identified variants is currently limited (53), but with resequen-
cing and identification of more loci such predictions could
improve. Together, gene and allele identification may even-
tually have clinical utility.
CONCLUSION
The first few years of GWA studies for cardiovascular and
metabolic traits have been filled with many successes.
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Dozens of genes identified previously by candidate gene or
linkage analyses have been convincingly replicated in large
studies with genome-wide levels of significance (Table 1).
Many new loci have been implicated in disease susceptibility
or trait variability, including some obvious likely functional
genes and some loci in gene deserts or only near genes
without known function. Although loci have been identified
with stringent statistical significance, the effect sizes are
modest and account for only a small fraction of variability
so far.
Several loci exhibit allelic heterogeneity, including both
common and rare alleles involved in disease. For example,
non-synonymous variants in MC4R are associated with
extreme obesity, and common variants .100 kb from the
gene are associated with modest changes in BMI and waist cir-
cumference. Allelic heterogeneity will increase as loci are
resequenced and additional rare alleles are identified. Some
loci have been identified as associated with more than one car-
diovascular or metabolic trait, such as the sets of SNPs near
the genes CDKN2A, CDKN2B and ANRIL that are associated
with T2D, CAD, MI, frailty and melanoma. Biological studies
will be important to evaluate the shared and unique risk alleles
at this and other loci. The abundance of new susceptibility loci
is ushering in an exciting new period in complex disease gen-
etics and providing many opportunities for future research.
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